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The Confirmatory Trial in Comparative-Effectiveness Research
Alan M. Garber, M.D., Ph.D., and Mark A. Hlatky, M.D. 
Despite the infusion of more than $1 billion 
through the American Recovery and Reinvestment 
Act of 2009 and the potential commitment of 
much more money, there will never be enough 
funding to perform all the comparative-effective-
ness studies that we want. The depth of interest 
in such studies became apparent when the Com-
mittee on Comparative Effectiveness Research 
Prioritization of the Institute of Medicine re-
ceived more than 1200 nominations of distinct 
topics to be among the first supported under the 
act.1 Thus, a critical question is how to choose 
the studies that will be supported with substan-
tial, but not unlimited, funds. How much should 
go to large database analyses, how much to med-
ical-literature reviews, and how much to large, 
rigorously designed, randomized clinical trials? 
And what questions should such studies address?
Seldom would confirmatory randomized trials 
rise to the top of a list of comparative-effective-
ness research priorities, especially if previous 
studies have produced negative results. Research 
should be pursued only if the value of the infor-
mation that it can be expected to reveal is great 
enough to justify the costs.2 The very term “con-
firmatory” implies that such studies are not ex-
pected to produce dramatic new insights. Fur-
thermore, randomized trials can be expensive. 
Comparative-effectiveness trials involve the usual 
challenges of screening and recruiting study sub-
jects, following them for many months — if not 
years  —  and  ascertaining  outcomes.  In  addi-
tion, many such trials must be large enough to 
detect  small  differences  in  clinical  outcomes, 
since a defining feature of such studies is a com-
parison with one or more “best,” often highly 
effective, alternatives, rather than with placebo 
alone.
The Immediate Risk-Stratification Improves 
Survival (IRIS) trial of the early use of an im-
plantable cardioverter–defibrillator (ICD) after 
myocardial infarction, reported on by Steinbeck 
and colleagues in this issue of the Journal, is such 
a confirmatory trial.3 The clinical hypothesis that 
it tested is an important one. In the first few 
months  after  hospital  discharge  for  an  acute 
myocardial infarction, patients are at higher risk 
for sudden cardiac death,4 a condition that ICDs 
treat effectively in other patient groups.5 How-
ever, the Defibrillator in Acute Myocardial Infarc-
tion Trial (DINAMIT) had previously shown that 
patients who were randomly assigned to an ICD 
early after an acute myocardial infarction did not 
live longer than controls, because the substantial 
reduction in the number of sudden cardiac deaths 
was offset by an excess of nonsudden cardiac 
deaths.6 This result stands in striking contrast 
to the mortality benefits of ICDs seen in other 
populations.  Although  DINAMIT  might  have 
been a “false negative” trial, crippled by a small 
sample size or design flaws, it is also possible 
that ICDs are ineffective immediately after an 
acute myocardial infarction, when recurrent is-
chemia may be more likely than a primary ar-
rhythmia to cause sudden death. Distinguishing 
between these possibilities required additional 
evidence from other randomized trials.
Just as in the DINAMIT trial, the IRIS trial 
showed no difference in overall mortality be-
tween patients who were randomly assigned to 
an ICD and patients who received conventional 
therapy early after an acute myocardial infarc-
tion.3 And, in IRIS, as in DINAMIT, the lower 
rate of sudden cardiac death among patients with 
an ICD was counterbalanced by a higher rate of 
nonsudden death. IRIS confirmed that ICD ther-
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apy is not effective early after an acute myocar-
dial infarction, notwithstanding the high risk of 
sudden death among such patients. This result 
is consistent with other data that show that the 
effectiveness of ICDs increases with the time since 
an acute myocardial infarction7 and that patients 
may die despite receiving appropriate ICD shocks.8
Few, if any, medical interventions work in every 
patient for the conditions they are designed to 
treat. As it determines which treatment is more 
effective, comparative-effectiveness research ad-
dresses the question: “In which patients?” Evi-
dence that an intervention is effective in one pop-
ulation  does  not  ensure  that  it  will  also  be 
effective  in  other  populations,  yet  therapies 
proved to work in narrowly defined clinical situ-
ations are often applied more broadly in practice 
(as “indication creep” or “off-label use”). Such 
therapies are sometimes extended to patients for 
whom the treatment is ineffective or harmful. 
By establishing the boundaries between the effec-
tive and ineffective applications of a treatment, 
comparative studies such as IRIS can improve 
health outcomes.
It could be argued that IRIS and other con-
firmatory trials will not change practice. Indeed, 
without this trial, it is unlikely that many pa-
tients would receive ICDs within 40 days after 
an acute myocardial infarction, since the previ-
ous randomized trial did not show a trend to-
ward efficacy6 and current clinical guidelines do 
not recommend it.9 Furthermore, if the goal of 
comparative-effectiveness research were to reduce 
health expenditures, in this case a new trial could 
have the opposite effect; that is, a positive result 
might lead to the increased adoption of an ex-
pensive intervention, whereas a negative result 
would only reinforce existing practice. However, 
to focus only on the budgetary impact would be 
to miss the point of comparative-effectiveness 
research. Such studies are designed to improve 
the safety and effectiveness of medical practices, 
not to show that the less expensive approaches 
to a clinical problem are always superior. Fur-
thermore, although the results of these studies 
can guide payment reforms and other policies 
to improve the effectiveness and quality of care, 
a more efficient health care system does not al-
ways mean lower expenditures. If IRIS had es-
tablished that ICDs are highly effective in this pa-
tient population, even this expensive intervention 
might have offered great value. That possibility 
is a strong reason to consider carrying out a new 
randomized trial, even after a negative study.
ICDs benefit selected patients, but the IRIS 
trial confirmed that they do not benefit all pa-
tients at high risk for sudden cardiac death. This 
result is worth knowing. It can direct efforts 
away from an expensive yet ineffective procedure 
toward either new or established alternatives. 
Confirmatory studies such as this one have a 
circumscribed but important role in comparative-
effectiveness research.
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